Study Shows That Females With Single Dose Of HPV Vaccine Obtain Similar Protection As Multiple Doses
Source: Thailand Medical News Dec 28, 2019 4 years, 11 months, 3 weeks, 4 days, 3 hours, 23 minutes ago
A recent study revealed that one dose of the
HPV vaccine may prevent infection from the potential
cancer-causing virus, according to research published in
JAMA Network Open from The University of Texas Health Science Center at Houston (UTHealth).
.jpg)
More than 34,800 new
cancer diagnoses are linked to
human papillomavirus (
HPV) annually just in America alone according to the Centers for Disease Control (CDC). The virus is thought to account for more than 90% of all cervical and anal
cancers, more than 60% of all penile
cancers, and approximately 70% of all oral
cancers.
Though results of the paper showed that a single dose may be as effective as the currently recommended two- or three-dose series, it's too early for people to rely on a single dose of the
vaccine for protection, according to senior author Dr Ashish A. Deshmukh, Ph.D., MPH, an Assistant Professor at UTHealth School of Public Health.
Dr Deshmukh told
Thailand Medical News, "
HPV vaccine coverage is less than 10% globally because of poor
vaccine uptake rates in many resource-limited countries. Ensuring boys and girls receive their first dose is a big challenge in several countries and a majority of adolescents are not able to complete the recommended series due to a lack of intensive infrastructure needed to administer two or three doses. If ongoing clinical trials provide evidence regarding sustained benefits of a one-dose regimen, then implications of single-dose strategy could be substantial for reducing the burden of these
cancers globally."
Though the study participants included only women, the CDC recommends a two-dose regimen for all children starting the series before age 15 or a three-dose regimen if the series is started between ages 16 to 26. The latest generation of
HPV vaccine can protect against nearly 90% of
cancer-causing
HPV infections. Yet, current vaccinations rates are less than ideal, half of people in the U.S. are not vaccinated against this common sexually transmitted infection.
Lead author Dr Kalyani Sonawane, Ph.D., who is an Assistant Professor at UTHealth School of Public Health commented, "The current
HPV vaccine dosing regimen can be cumbersome for people to understand. If one dose is proven effective in trials, the vaccine regimen will be simplified. This will help improve the coverage rate among adolescents that are currently below the Healthy People 2020 goal and possibly will also increase the momentum of uptake in the newly approved age group."
Reference : Kalyani Sonawane et al. Prevalence of Human Papillomavirus Infection by Number of Vaccine Doses Among US Women.&a
mp;nbsp;JAMA Network Open 2019;2(12):e1918571. DOI: 10.1001/jamanetworkopen.2019.18571
